Singapore-headquartered healthcare investor August Global Partners (AGP) is investing in Vietnam=based genomic testing company Gene Solutions (GS) through a proprietary funding round.

Gene Solutions said in a statement that the duo have signed a memorandum of understanding (MoU) for the partnership.

Under the MoU, GS will support broader adoption of precision medicine and targeted therapeutics in Asia through the development of a suite of artificial intelligence (AI) technologies that encompass a scientific knowledge base, large language models (LLM), multi-omics insights, and clinical database to push the boundaries of next-generation sequencing (NGS) services.

The AI suite, named DNAsphere.AI, was developed by GS through years of clinical research partnerships and DNA testing expertise across both reproductive health and oncology verticals.

With this AI suite, GS can reduce sequencing costs while significantly improving test performance, consequently increasing the accessibility of personalized solutions.

Meanwhile, AGP who is investing in GS through a proprietary funding round, will assist them in enhancing the performance of their oncology solutions by providing access to world-class research resources and regional partners.

This will enable GS to further validate its test accuracy and implement the DNAsphere.AI suite in personalized cancer treatment applications.

It is noted that GS is now expanding its product portfolio in personalized cancer care to the global market.

This includes their renowned early cancer detection (SPOT-MAS) and cancer monitoring tests (K-TRACK).

More recently, the company announced the launch of single-cancer early detection (SCED) tests developed with AI-driven ctDNA technology, aimed at improving early cancer screening adherence in asymptomatic populations.

GS also has ongoing programs with biopharma leaders to co-develop novel cancer therapeutics, such as targeted cancer drugs, neoantigen vaccines, and cell therapies.

“Cancer is a debilitating disease that has impacted many of our loved ones or ourselves profoundly. This partnership is a pivotal milestone in our company’s mission to provide advanced and accessible oncology solutions,

“By combining our genomic expertise with AGP’s investment and network, we aim to make blood-based cancer screening and treatment monitoring tests more accurate and more affordable,” said Dr. Nguyen Hoai Nghia, Chief Executive Officer and Chairman of GS.

GS is a biotech company in Asia, known for its innovative reproductive and oncology solutions.

The firm has provided over 2,000,000 cell-free DNA tests in the region, including more than 60,000 tumor profiling tests and over 20,000 multi-cancer early detection tests.

“Genomic technologies can revolutionize cancer management via earlier detection and personalized treatment insights, and GS is an emerging leader in providing affordable high-quality tests,” said Dr. Basil Lui, Founding Partner of AGP.,

As more tests are delivered and validated, he said GS can further build competitive advantage from the AI flywheel effect.

“Our investment underscores our commitment to visionary entrepreneurs and innovation-led healthcare solutions,” he added.

As a growth-oriented, global investment firm from Singapore, AGP has an extensive network cultivated through decades of global investment experience in areas such as healthcare-related technologies and bio-innovations.

Backed by a diverse array of financial investors, conglomerates, and institutions, the firm provides value-added capital to the next generation of founders and innovators who are shaping the future of healthcare in Asia and the world.

#Genomics #CancerDetection #PrecisionMedicine #HealthcareInnovation #AIinHealthcare